Tanager Wealth Management LLP Decreases Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Tanager Wealth Management LLP reduced its stake in Centessa Pharmaceuticals by 14.1%, selling 98,052 shares and holding a total of 598,044 shares, which constitutes about 0.9% of its holdings.
• Several hedge funds have increased their positions in Centessa Pharmaceuticals, with 82.01% of the stock now owned by institutional investors.
• Centessa Pharmaceuticals reported (-0.38) earnings per share in its recent quarterly results, falling short of consensus estimates, while analysts maintain a consensus rating of "Buy" with a target price averaging around $32.38.

Tanager Wealth Management LLP trimmed its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 14.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 598,044 shares of the company's stock after selling 98,052 shares during the quarter. Centessa Pharmaceuticals accounts for approximately 0.9% of Tanager Wealth Management LLP's holdings, making the stock its 24th biggest holding. Tanager Wealth Management LLP owned about 0.45% of Centessa Pharmaceuticals worth $7,858,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in CNTA. Ameriprise Financial Inc. purchased a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth $320,000. Squarepoint Ops LLC boosted its holdings in Centessa Pharmaceuticals by 33.2% in the fourth quarter. Squarepoint Ops LLC now owns 26,806 shares of the company's stock valued at $449,000 after acquiring an additional 6,685 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Centessa Pharmaceuticals by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 115,107 shares of the company's stock valued at $1,928,000 after acquiring an additional 14,494 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Centessa Pharmaceuticals by 1,509.6% in the first quarter. GAMMA Investing LLC now owns 61,762 shares of the company's stock valued at $888,000 after acquiring an additional 57,925 shares in the last quarter. Finally, HighMark Wealth Management LLC boosted its holdings in Centessa Pharmaceuticals by 41.9% in the first quarter. HighMark Wealth Management LLC now owns 235,785 shares of the company's stock valued at $3,391,000 after acquiring an additional 69,650 shares in the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, General Counsel Iqbal J. Hussain sold 20,000 shares of the company's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $20.01, for a total value of $400,200.00. Following the transaction, the general counsel owned 105,386 shares in the company, valued at $2,108,773.86. The trade was a 15.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $15.56, for a total transaction of $155,600.00. Following the completion of the transaction, the insider owned 122,279 shares in the company, valued at approximately $1,902,661.24. The trade was a 7.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 205,286 shares of company stock worth $3,993,345 over the last quarter. 7.09% of the stock is owned by insiders.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $22.62 on Thursday. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $9.60 and a 12 month high of $24.57. The stock has a market cap of $3.03 billion, a PE ratio of -12.64 and a beta of 1.56. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32. The company's fifty day moving average price is $18.81 and its 200-day moving average price is $15.24.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). On average, equities analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Analyst Ratings Changes

CNTA has been the topic of several recent analyst reports. Chardan Capital reiterated a "buy" rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Truist Financial initiated coverage on shares of Centessa Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $30.00 price target on the stock. Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, September 3rd. Wall Street Zen cut shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Finally, Wells Fargo & Company assumed coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, September 3rd. They issued an "overweight" rating and a $31.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $32.38.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.